 |
|
|
| |
Simeprevir with Peginterferon/ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-based Therapy: Results from PROMISE, a Phase III Trial
|
| |
| |
Reported by Jules Levin
DDW May 18-21 2013 Orlando Florida
Eric Lawitz1, Xavier Forns2, Stefan Zeuzem3, Ed Gane4, Jean Pierre Bronowicki5, Pietro Andreone6, Andrzej Horban7, Ashley Brown8,
Monika Peeters9, Oliver Lenz9, Sivi Ouwerkerk-Mahadevan10, Ronald Kalmeijer11, Maria Beumont-Mauviel9
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 5INSERM U954, Université de Lorraine, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France; 6Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Italy; 7Medical University of Warsaw, Wolska, Warsaw, Poland; 8Imperial College Healthcare NHS Trust, London, United Kingdom; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Janssen Research & Development, Beerse, Belgium. 11Janssen Global Services, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
